Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Lowered to $2.00 at D. Boral Capital

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price target reduced by D. Boral Capital from $3.00 to $2.00 in a research report sent to investors on Tuesday morning,Benzinga reports. D. Boral Capital currently has a buy rating on the stock.

A number of other research firms have also issued reports on LCTX. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Friday, January 31st. Maxim Group reduced their price objective on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, January 10th.

Lineage Cell Therapeutics Stock Down 0.3 %

NYSEAMERICAN:LCTX opened at $0.65 on Tuesday. Lineage Cell Therapeutics has a 12-month low of $0.48 and a 12-month high of $1.61. The company has a market cap of $144.18 million, a P/E ratio of -5.45 and a beta of 1.21.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LCTX. HighTower Advisors LLC raised its stake in shares of Lineage Cell Therapeutics by 49.5% in the 4th quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock worth $29,000 after buying an additional 19,100 shares in the last quarter. Fort Sheridan Advisors LLC raised its stake in shares of Lineage Cell Therapeutics by 71.5% in the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock worth $28,000 after buying an additional 23,000 shares in the last quarter. Red Crane Wealth Management LLC bought a new stake in shares of Lineage Cell Therapeutics in the 4th quarter worth $171,000. Atria Wealth Solutions Inc. bought a new stake in shares of Lineage Cell Therapeutics in the 4th quarter worth $29,000. Finally, Defender Capital LLC. raised its stake in shares of Lineage Cell Therapeutics by 19.2% in the 4th quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock worth $2,997,000 after buying an additional 961,150 shares in the last quarter. Institutional investors and hedge funds own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.